BMPS
(Synonyms: 3-马来酰亚胺基丙酸羟基琥珀酰亚胺酯) 目录号 : GC38739
BMPS 是一种抗体偶联药物 (ADC) 的不可降解的连接桥 (ADC linker)。
Cas No.:55750-62-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
BMPS is a nonclaevable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
| Cas No. | 55750-62-4 | SDF | |
| 别名 | 3-马来酰亚胺基丙酸羟基琥珀酰亚胺酯 | ||
| Canonical SMILES | O=C(ON1C(CCC1=O)=O)CCN2C(C=CC2=O)=O | ||
| 分子式 | C11H10N2O6 | 分子量 | 266.21 |
| 溶解度 | DMSO: ≥ 45 mg/mL (169.04 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7564 mL | 18.7822 mL | 37.5643 mL |
| 5 mM | 0.7513 mL | 3.7564 mL | 7.5129 mL |
| 10 mM | 0.3756 mL | 1.8782 mL | 3.7564 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Two Modulators of Skeletal Development: BMPS and Proteoglycans
J Dev Biol 2022 Apr 6;10(2):15.PMID:35466193DOI:10.3390/jdb10020015.
During embryogenesis, skeletal development is tightly regulated by locally secreted growth factors that interact with proteoglycans (PGs) in the extracellular matrix (ECM). Bone morphogenetic proteins (BMPS) are multifunctional growth factors that play critical roles in cartilage maturation and bone formation. BMP signals are transduced from plasma membrane receptors to the nucleus through both canonical Smad and noncanonical p38 mitogen-activated protein kinase (MAPK) pathways. BMP signalling is modulated by a variety of endogenous and exogenous molecular mechanisms at different spatiotemporal levels and in both positive and negative manners. As an endogenous example, BMPS undergo extracellular regulation by PGs, which generally regulate the efficiency of ligand-receptor binding. BMP signalling can also be exogenously perturbed by a group of small molecule antagonists, such as dorsomorphin and its derivatives, that selectively bind to and inhibit the intracellular kinase domain of BMP type I receptors. In this review, we present a current understanding of BMPS and PGs functions in cartilage maturation and osteoblast differentiation, highlighting BMP-PG interactions. We also discuss the identification of highly selective small-molecule BMP receptor type I inhibitors. This review aims to shed light on the importance of BMP signalling and PGs in cartilage maturation and bone formation.
BMPS and the muscle-bone connection
Bone 2015 Nov;80:37-42.PMID:26036170DOI:10.1016/j.bone.2015.05.023.
Muscle and bone are two intimately connected tissues. A coordinated interplay between these tissues at mechanical levels is required for their development, function and ageing. Evidence is emerging that several genes and molecular pathways exert a pleiotropic effect on both muscle and bone. Bone morphogenetic proteins (BMPS) are secreted signal factors belonging to the transforming growth factor β (TGFβ) superfamily. BMPS have an essential role during bone and cartilage formation and maintenance. Recently, we and others have demonstrated that the BMP pathway also has a role in controlling adult skeletal muscle mass. Thus, BMPS become crucial regulators of both bone and muscle formation and homeostasis. In this review we will discuss the signalling downstream BMP and its role in muscle-bone interaction. This article is part of a Special Issue entitled "Muscle Bone Interactions".
BMPS and their clinical potentials
BMB Rep 2011 Oct;44(10):619-34.PMID:22026995DOI:10.5483/BMBRep.2011.44.10.619.
Bone morphogenetic protein (BMP) signaling in diseases is the subject of an overwhelming array of studies. BMPS are excellent targets for treatment of various clinical disorders. Several BMPS have already been shown to be clinically beneficial in the treatment of a variety of conditions, including BMP-2 and BMP-7 that have been approved for clinical application in nonunion bone fractures and spinal fusions. With the use of BMPS increasingly accepted in spinal fusion surgeries, other therapeutic approaches targeting BMP signaling are emerging beyond applications to skeletal disorders. These approaches can further utilize next-generation therapeutic tools such as engineered BMPS and ex vivo- conditioned cell therapies. In this review, we focused to provide insights into such clinical potentials of BMPS in metabolic and vascular diseases, and in cancer. [BMB reports 2011; 44(10): 619-634].
BMPS and liver: more questions than answers
Curr Pharm Des 2012;18(27):4114-25.PMID:22630083DOI:10.2174/138161212802430503.
Bone morphogenetic proteins (BMPS) belong to the TGF-β superfamily and were first discovered as potent bone homeostasis regulators for their ability to induce endochondral bone formation, ectopic bone formation and fracture repair. A preeminent role of BMP signaling in developmental control of cell type specification, differentiation and organogenesis is also well established. More recently, a role for BMPS in adult tissue homeostasis has started being revealed. Thus, new studies show that BMPS regulate many cellular processes such as proliferation, apoptosis, differentiation and migration in many tissues and organs. As a consequence, dysregulation of BMP activity can have pathological consequences, and there is mounting evidence for the involvement of BMPS in different human diseases. In this review, we have focused on summarizing the present knowledge on the relevance of BMPS in liver physiology and pathophysiology, from the well-recognized role in liver development to the emerging contribution to the function and dysfunction of the adult liver. While no doubts seem to rise about the regulatory activities of BMPS on metabolic pathways in the liver, potential pro- and anti-fibrogenic and tumorigenic actions will likely be a matter of debate during coming years. Collectively, the work here presented provides the basis to consider BMPS as potential targets of intervention in liver diseases.
Autograft versus BMPS for the treatment of non-unions: what is the evidence?
Injury 2013 Jan;44 Suppl 1:S40-2.PMID:23351869DOI:10.1016/S0020-1383(13)70009-3.
Autograft is considered the gold standard in non-union treatment. However, it is associated with significant morbidity and limited biological activity. The introduction of bone morphogenetic proteins (BMPS) has added a valuable tool to the surgeon's possibilities. The initial expectations of the effectiveness of BMPS were high, but over the years the union rate of BMPS was shown to be comparable with autograft. In this overview, both treatment modalities are compared. The off-label use of BMPS, the combination of BMPS and autograft, and the economic perspective of BMP use are summarized. In their current formulation, BMPS are an effective alternative for autograft in selected cases. The beneficial effect outweighs the economic costs. Widening of the indication to other long bone non-unions and new formulations are expected in the nearby future.